<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04308148</url>
  </required_header>
  <id_info>
    <org_study_id>2019-10029</org_study_id>
    <nct_id>NCT04308148</nct_id>
  </id_info>
  <brief_title>Does Medical Cannabis Reduce Opioid Use in Adults With Pain</brief_title>
  <acronym>ReLeaf-E</acronym>
  <official_title>Does Medical Cannabis Reduce Opioid Use in Adults With Pain: An Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Laura and John Arnold Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vireo Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will examine how medical cannabis use affects opioid analgesic use. This landmark
      study will be among the first to examine the effect of medical cannabis with different
      THC/CBD content on opioid use as well as adverse events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine how medical cannabis use affects opioid analgesic use, with
      particular attention to THC/CBD content and adverse events. We will enroll adults with (a)
      severe or chronic neuropathic or joint pain, (b) prescribed opioid analgesic use, (c) new
      certification for medical cannabis, and (d) newly dispensed soft gel capsule products from
      Vireo (medical cannabis dispensary) (including a high THC:low CBD product, an equal THC:CBD
      product, and a low THC:high CBD product). Over the 14 weeks, data sources will include
      questionnaires; medical, pharmacy, and Prescription Monitoring Program (PMP) records; and
      urine samples. The primary independent variable will be type of soft gel capsule product, and
      the primary outcome will be cumulative opioid analgesic dose.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 31, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Opioid analgesic use</measure>
    <time_frame>Opioid analgesic use will be weekly cumulative dose of opioid analgesics over 14 weeks.</time_frame>
    <description>The primary outcome will be opioid analgesic use.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Adverse events will be over 14 weeks</time_frame>
    <description>(e.g. Cannabis use disorder, illicit drug use, diversion of medical cannabis, accidents and injuries)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Opioid Use</condition>
  <condition>Marijuana</condition>
  <condition>Chronic Pain</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with chronic pain, who are taking opioids and are newly certified for medical
        cannabis in New York.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  English or Spanish fluency

          -  New certification for medical cannabis within 90 days

          -  No medical cannabis dispensed or used within the previous 6 months

          -  New soft-gel capsule product dispensed at Vireo

          -  Medical cannabis qualifying conditions or complications of &quot;chronic or severe pain&quot; or
             &quot;pain that degrades health and functional capability as an alternative to opioid use
             or substance use disorder&quot;

          -  Joint or neuropathic pain

          -  Current severe pain

          -  Dispensed opioid analgesics within the last 30 days

          -  Self-reported use of opioid analgesics

        Exclusion Criteria:

          -  Inability to provide informed consent

          -  Inability to complete study visits over 14 weeks

          -  Qualifying conditions for medical cannabis in NY that are likely to cause unique pain
             syndromes

          -  Terminal illness

          -  Current or prior psychotic disorder

          -  Current or prior buprenorphine or methadone treatment for opioid use disorder

          -  Allergies to tapioca or coconut
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chinazo Cunningham, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chinazo Cunningham, MD, MS</last_name>
    <phone>718-920-5971</phone>
    <email>chinazo.cunningham@einsteinmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giovanna DiFrancesca</last_name>
    <phone>718-920-5763</phone>
    <email>giovanna.calderon@einsteinmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Montefiore Health System</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10451</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Chinazo Cunningham, MD, MS</last_name>
      <phone>718-920-5971</phone>
      <email>chinazo.cunningham@einsteinmed.org</email>
    </contact>
    <contact_backup>
      <last_name>Giovanna DiFrancesca</last_name>
      <phone>718-920-5763</phone>
      <email>giovanna.calderon@einsteinmed.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 12, 2020</study_first_submitted>
  <study_first_submitted_qc>March 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Albert Einstein College of Medicine</investigator_affiliation>
    <investigator_full_name>Chinazo Cunningham</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

